...to its toolbox through a pair of deals (see “Pair of Trispecific Deals” ). From Harpoon Therapeutics Inc....

...in include neoantigen T cell therapy company Pact Pharma Inc.; next-generation T cell engager play Harpoon Therapeutics Inc....

...No. 7508 ). Trispecific engager platforms may also offer early hints of efficacy at ASCO. Harpoon Therapeutics Inc....

...join the board. Bethell was CSO of Medivir AB (SSE:MVIR B); Sacks is CMO of Harpoon Therapeutics Inc....

...with Dragonfly, could mark the pharma’s entrance into NK cell engagers. Under the deal with Harpoon Therapeutics Inc....
...with Celgene Corp. and Merck & Co. Inc. (NYSE:MRK). Elizabeth S. Eaton, Staff Writer AbbVie Inc. Dragonfly Therapeutics Inc. Harpoon Therapeutics Inc. trispecific T...

...Inc. (NASDAQ:TCRR) 2/13/19 $86.3 $359.1 $342.6 -5% Avedro Inc. (NASDAQ:AVDR) 2/13/19 $70.0 $238.8 $336.0 41% Harpoon Therapeutics Inc....

...ADC Therapeutics S.A. / AstraZeneca plc (LSE:AZN; NYSE:AZN) MEDI3726 Ph I/II Monotherapy and Xtandi None Harpoon Therapeutics Inc....

...said the firm used OIF and BioVentures 2014 to co-invest in companies including cancer plays Harpoon Therapeutics Inc....

...end of the government shutdown (see "Broken Window" ). Harpoon Therapeutics Inc. (NASDAQ:HARP), South San Francisco, Calif. Paul Bonanos Harpoon Therapeutics Inc....

...have resumed on NASDAQ following the end of the government shutdown (see "Broken Window" ). Paul Bonanos Harpoon Therapeutics Inc. IPO...